Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Cancer stem cells and their unique role in metastatic spread.

Steinbichler TB, Savic D, Dudás J, Kvitsaridze I, Skvortsov S, Riechelmann H, Skvortsova II.

Semin Cancer Biol. 2019 Sep 12. pii: S1044-579X(19)30264-0. doi: 10.1016/j.semcancer.2019.09.007. [Epub ahead of print] Review.

PMID:
31521746
2.

Targeting Cancer Stem Cells Pathways for the Effective Treatment of Cancer.

Dwivedi AR, Thakur A, Kumar V, Skvortsova I, Kumar V.

Curr Drug Targets. 2019 Aug 21. doi: 10.2174/1389450120666190821160730. [Epub ahead of print]

PMID:
31433755
3.

Pleiotropic Effects of Epithelial Mesenchymal Crosstalk on Head and Neck Cancer: EMT and beyond.

Steinbichler TB, Savic D, Dejaco D, Romani A, Kofler B, Skvortsova II, Riechelmann H, Dudas J.

Cancer Microenviron. 2019 Jul 11. doi: 10.1007/s12307-019-00228-y. [Epub ahead of print]

PMID:
31297730
4.

Therapy resistance mediated by exosomes.

Steinbichler TB, Dudás J, Skvortsov S, Ganswindt U, Riechelmann H, Skvortsova II.

Mol Cancer. 2019 Mar 30;18(1):58. doi: 10.1186/s12943-019-0970-x. Review.

5.

The CD98 Heavy Chain Is a Marker and Regulator of Head and Neck Squamous Cell Carcinoma Radiosensitivity.

Digomann D, Kurth I, Tyutyunnykova A, Chen O, Löck S, Gorodetska I, Peitzsch C, Skvortsova II, Negro G, Aschenbrenner B, Eisenhofer G, Richter S, Heiden S, Porrmann J, Klink B, Schwager C, Dowle AA, Hein L, Kunz-Schughart LA, Abdollahi A, Lohaus F, Krause M, Baumann M, Linge A, Dubrovska A.

Clin Cancer Res. 2019 May 15;25(10):3152-3163. doi: 10.1158/1078-0432.CCR-18-2951. Epub 2019 Jan 22.

PMID:
30670494
6.

Special Issue "Cancer Stem Cells: Impact on Treatment".

Skvortsova I.

Semin Cancer Biol. 2018 Dec;53:iii-iv. doi: 10.1016/j.semcancer.2018.11.008. No abstract available.

PMID:
30509407
7.

Therapy resistance mediated by cancer stem cells.

Steinbichler TB, Dudás J, Skvortsov S, Ganswindt U, Riechelmann H, Skvortsova II.

Semin Cancer Biol. 2018 Dec;53:156-167. doi: 10.1016/j.semcancer.2018.11.006. Epub 2018 Nov 22. Review.

PMID:
30471331
8.

In the beginning, there was chaos: A perspective on the development of immuno-oncological biomarkers.

Salgado R, Harris L, Skvortsova I, Denkert C, Loi S.

Semin Cancer Biol. 2018 Oct;52(Pt 2):v-vi. doi: 10.1016/j.semcancer.2018.08.004. Epub 2018 Aug 4. No abstract available.

PMID:
30086389
9.

Predicting and Understanding Cancer Response to Treatment.

Callari M, Gandellini P, Skvortsova I, Span PN.

Dis Markers. 2018 May 29;2018:6159214. doi: 10.1155/2018/6159214. eCollection 2018. No abstract available.

10.

Fractionated Radiation of Primary Prostate Basal Cells Results in Downplay of Interferon Stem Cell and Cell Cycle Checkpoint Signatures.

Guggenberger F, van de Werken HJG, Erb HHH, Cappellano G, Trattnig K, Handle F, Peer S, Schäfer G, Jenster G, Culig Z, Skvortsova I, Santer FR.

Eur Urol. 2018 Dec;74(6):847-849. doi: 10.1016/j.eururo.2018.06.002. Epub 2018 Jun 18. No abstract available.

PMID:
29914715
11.

Concise Review: Prostate Cancer Stem Cells: Current Understanding.

Skvortsov S, Skvortsova II, Tang DG, Dubrovska A.

Stem Cells. 2018 Oct;36(10):1457-1474. doi: 10.1002/stem.2859. Epub 2018 Aug 27. Review.

PMID:
29845679
12.

Olaparib is effective in combination with, and as maintenance therapy after, first-line endocrine therapy in prostate cancer cells.

Feiersinger GE, Trattnig K, Leitner PD, Guggenberger F, Oberhuber A, Peer S, Hermann M, Skvortsova I, Vrbkova J, Bouchal J, Culig Z, Santer FR.

Mol Oncol. 2018 Apr;12(4):561-576. doi: 10.1002/1878-0261.12185. Epub 2018 Mar 15.

13.

Editorial: Recent Trends in Anticancer Drug Development: Challenges and Opportunities.

Skvortsova II, Kumar V.

Curr Med Chem. 2017 Jan 11;24(42):4727-4728. doi: 10.2174/092986732442180111141255. No abstract available.

PMID:
29378506
14.

Special issue: Progress in biological understanding of cancer metastasis.

Skvortsova II.

Semin Cancer Biol. 2017 Jun;44:1-2. doi: 10.1016/j.semcancer.2017.05.007. Epub 2017 May 20. No abstract available.

PMID:
28536032
15.

Promising Targets in Anti-cancer Drug Development: Recent Updates.

Kumar B, Singh S, Skvortsova I, Kumar V.

Curr Med Chem. 2017;24(42):4729-4752. doi: 10.2174/0929867324666170331123648. Review.

PMID:
28393696
16.

The role of exosomes in cancer metastasis.

Steinbichler TB, Dudás J, Riechelmann H, Skvortsova II.

Semin Cancer Biol. 2017 Jun;44:170-181. doi: 10.1016/j.semcancer.2017.02.006. Epub 2017 Feb 13. Review.

PMID:
28215970
17.

Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on their Therapeutic Potential and Clinical Trials.

Kumar B, Kumar R, Skvortsova I, Kumar V.

Curr Cancer Drug Targets. 2017;17(4):357-375. doi: 10.2174/1568009616666160928110818. Review.

PMID:
27697026
18.

Sex Differences in Renal Proximal Tubular Cell Homeostasis.

Seppi T, Prajczer S, Dörler MM, Eiter O, Hekl D, Nevinny-Stickel M, Skvortsova I, Gstraunthaler G, Lukas P, Lechner J.

J Am Soc Nephrol. 2016 Oct;27(10):3051-3062. Epub 2016 Apr 28.

19.

Screening and identification of molecular targets for cancer therapy.

Abdelmoez A, Coraça-Huber DC, Thurner GC, Debbage P, Lukas P, Skvortsov S, Skvortsova II.

Cancer Lett. 2017 Feb 28;387:3-9. doi: 10.1016/j.canlet.2016.03.002. Epub 2016 Mar 8. Review.

PMID:
26968248
20.

Editorial.

Skvortsova I.

Semin Cancer Biol. 2015 Dec;35:1-2. doi: 10.1016/j.semcancer.2015.10.001. Epub 2015 Oct 9. No abstract available.

PMID:
26455668
21.

Radiation resistance: Cancer stem cells (CSCs) and their enigmatic pro-survival signaling.

Skvortsova I, Debbage P, Kumar V, Skvortsov S.

Semin Cancer Biol. 2015 Dec;35:39-44. doi: 10.1016/j.semcancer.2015.09.009. Epub 2015 Sep 25. Review.

PMID:
26392376
22.

Proteomic approach to understand metastatic spread.

Skvortsov S, Arnold CR, Debbage P, Lukas P, Skvortsova I.

Proteomics Clin Appl. 2015 Dec;9(11-12):1069-77. doi: 10.1002/prca.201400128. Epub 2015 Jun 16. Review.

PMID:
25914211
23.

Rac1 as a multifunctional therapeutic target to prevent and combat cancer metastasis.

Arnold CR, Abdelmoez A, Thurner G, Debbage P, Lukas P, Skvortsov S, Skvortsova II.

Oncoscience. 2014 Aug 21;1(8):513-521. eCollection 2014.

24.

It is well established that affected intracellular signaling is associated with carcinogenesis, cancer progression and tumor sensitivity to currently existing therapeutic approaches.

Skvortsova I.

Semin Cancer Biol. 2015 Apr;31:1-2. doi: 10.1016/j.semcancer.2014.12.001. Epub 2015 Jan 3. No abstract available.

PMID:
25559282
25.

[Budd-Chiari syndrome (case report)].

Kamalova AA, Shakirova AR, Khamidullin AF, Skvortsova IV, Khomiakov AE.

Eksp Klin Gastroenterol. 2014;(1):113-6. Russian.

PMID:
25518467
26.

Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours.

Baro M, de Llobet LI, Figueras A, Skvortsova I, Mesia R, Balart J.

Br J Cancer. 2014 Sep 23;111(7):1310-8. doi: 10.1038/bjc.2014.432. Epub 2014 Jul 31.

27.

Crosstalk between DNA repair and cancer stem cell (CSC) associated intracellular pathways.

Skvortsov S, Debbage P, Lukas P, Skvortsova I.

Semin Cancer Biol. 2015 Apr;31:36-42. doi: 10.1016/j.semcancer.2014.06.002. Epub 2014 Jun 17. Review.

PMID:
24954010
28.

Rac1 as a potential therapeutic target for chemo-radioresistant head and neck squamous cell carcinomas (HNSCC).

Skvortsov S, Dudás J, Eichberger P, Witsch-Baumgartner M, Loeffler-Ragg J, Pritz C, Schartinger VH, Maier H, Hall J, Debbage P, Riechelmann H, Lukas P, Skvortsova I; EORTC PathoBiology Group.

Br J Cancer. 2014 May 27;110(11):2677-87. doi: 10.1038/bjc.2014.221. Epub 2014 May 1.

29.

Putative biomarkers and therapeutic targets associated with radiation resistance.

Skvortsov S, Debbage P, Cho WC, Lukas P, Skvortsova I.

Expert Rev Proteomics. 2014 Apr;11(2):207-14. doi: 10.1586/14789450.2014.893194. Epub 2014 Feb 25. Review.

PMID:
24564737
30.

Proteomics of cancer stem cells.

Skvortsov S, Debbage P, Skvortsova I.

Int J Radiat Biol. 2014 Aug;90(8):653-8. doi: 10.3109/09553002.2013.873559. Epub 2014 May 12. Review.

PMID:
24350919
31.

Profilin 1: do we have a novel proteome-found biomarker predicting response to anticancer therapy?

Skvortsova I.

Proteomics. 2013 Jul;13(14):2069-71. doi: 10.1002/pmic.201300165.

PMID:
23677805
32.

Radioresistant head and neck squamous cell carcinoma cells: intracellular signaling, putative biomarkers for tumor recurrences and possible therapeutic targets.

Skvortsov S, Jimenez CR, Knol JC, Eichberger P, Schiestl B, Debbage P, Skvortsova I, Lukas P.

Radiother Oncol. 2011 Oct;101(1):177-82. doi: 10.1016/j.radonc.2011.05.067. Epub 2011 Jun 21.

PMID:
21700351
33.

Feasibility and toxicity of concomitant radio/immunotherapy with MabThera (Rituximab®) for patients with non-Hodkin's Lymphoma: results of a prospective phase I/II study.

Haidenberger A, Fromm-Haidenberger S, de Vries A, Popper BA, Steurer M, Skvortsova I, Kantner J, Gunsilius E, Lukas P.

Strahlenther Onkol. 2011 May;187(5):300-5. doi: 10.1007/s00066-011-2169-y. Epub 2011 Apr 26.

PMID:
21544528
34.

[Transplantation of the bone marrow from a HLA-compatible unrelated donor after immunoablative conditioning in children with acquired aplastic anemia unresponsive to combined immunosuppressive therapy: preliminary results].

Novichkova GA, Maschan MA, Shipitsyna IP, Skvortsova IuV, Persiantseva MI, Lebedeva LL, Bobrynina VO, Baĭdil'dina DD, Goronkova OV, Solopova GG, Khachatrian LA, Petrova UN, Suntsova EV, Kalinina II, Sinitsyna VV, Skorobogatova EV, Balashov DN, Dyshlevaia ZM, Shelikhova LN, Kurnikova EE, Trakhtman PE, Maschan AA.

Ter Arkh. 2010;82(7):41-7. Russian.

PMID:
20853608
35.

[Results of hematopoietic cell transplantation in the first complete remission in children with acute myeloid leukemia from an intermediate risk group].

SDyshlevaia ZM, Skorobogatova EV, Maschan MA, Shipitsyna IP, Skvortsova IuV, Trakhtman PE, Balashov DN, Pashko IuV, Kurnikova EE, Suntsova EV, Goronkova OV, Solopova GG, Baĭdil'dina DD, Kalinina II, Khachatrian LA, Shneĭder MM, Maschan AA.

Ter Arkh. 2010;82(7):34-40. Russian.

PMID:
20853607
36.

Epithelial-to-mesenchymal transition and c-myc expression are the determinants of cetuximab-induced enhancement of squamous cell carcinoma radioresponse.

Skvortsova I, Skvortsov S, Raju U, Stasyk T, Riesterer O, Schottdorf EM, Popper BA, Schiestl B, Eichberger P, Debbage P, Neher A, Bonn GK, Huber LA, Milas L, Lukas P.

Radiother Oncol. 2010 Jul;96(1):108-15. doi: 10.1016/j.radonc.2010.04.017. Epub 2010 May 5.

PMID:
20451273
37.

Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib.

Loeffler-Ragg J, Mueller D, Gamerith G, Auer T, Skvortsov S, Sarg B, Skvortsova I, Schmitz KJ, Martin HJ, Krugmann J, Alakus H, Maser E, Menzel J, Hilbe W, Lindner H, Schmid KW, Zwierzina H.

Mol Cancer Ther. 2009 Jul;8(7):1995-2006. doi: 10.1158/1535-7163.MCT-08-0987. Epub 2009 Jun 30.

38.

Oxidative damage and cutaneous reactions during radiotherapy in combination with cetuximab.

Skvortsova I.

Radiother Oncol. 2009 Feb;90(2):281-2. doi: 10.1016/j.radonc.2008.12.006. Epub 2009 Jan 17. No abstract available.

PMID:
19150740
39.

Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells.

Skvortsova I, Skvortsov S, Stasyk T, Raju U, Popper BA, Schiestl B, von Guggenberg E, Neher A, Bonn GK, Huber LA, Lukas P.

Proteomics. 2008 Nov;8(21):4521-33. doi: 10.1002/pmic.200800113.

PMID:
18821526
40.

Cetuximab inhibits thymidylate synthase in colorectal cells expressing epidermal growth factor receptor.

Skvortsov S, Sarg B, Lindner H, Lukas P, Hilbe W, Zwierzina H, Skvortsova I.

Proteomics Clin Appl. 2008 Jun;2(6):908-14. doi: 10.1002/prca.200780034.

PMID:
21136888
41.

MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps.

Kasibhatla S, Baichwal V, Cai SX, Roth B, Skvortsova I, Skvortsov S, Lukas P, English NM, Sirisoma N, Drewe J, Pervin A, Tseng B, Carlson RO, Pleiman CM.

Cancer Res. 2007 Jun 15;67(12):5865-71.

42.

Antitumor activity of CTFB, a novel anticancer agent, is associated with the down-regulation of nuclear factor-kappaB expression and proteasome activation in head and neck squamous carcinoma cell lines.

Skvortsov S, Skvortsova I, Stasyk T, Schiefermeier N, Neher A, Gunkel AR, Bonn GK, Huber LA, Lukas P, Pleiman CM, Zwierzina H.

Mol Cancer Ther. 2007 Jun;6(6):1898-908.

43.

99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours.

von Guggenberg E, Dietrich H, Skvortsova I, Gabriel M, Virgolini IJ, Decristoforo C.

Eur J Nucl Med Mol Imaging. 2007 Aug;34(8):1209-18. Epub 2007 Feb 17.

PMID:
17308920
44.

Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and - independent mechanisms.

Skvortsova I, Skvortsov S, Popper BA, Haidenberger A, Saurer M, Gunkel AR, Zwierzina H, Lukas P.

J Radiat Res. 2006 Jun;47(2):183-96.

45.

Irreversible pan-ErbB tyrosine kinase inhibitor CI-1033 induces caspase-independent apoptosis in colorectal cancer DiFi cell line.

Skvortsov S, Skvortsova I, Sarg B, Loeffler-Ragg J, Lindner H, Lukas P, Tabernero J, Zwierzina H.

Apoptosis. 2005 Oct;10(5):1175-86.

PMID:
16151650
46.

Gefitinib-responsive EGFR-positive colorectal cancers have different proteome profiles from non-responsive cell lines.

Loeffler-Ragg J, Skvortsov S, Sarg B, Skvortsova I, Witsch-Baumgartner M, Mueller D, Lindner H, Zwierzina H.

Eur J Cancer. 2005 Oct;41(15):2338-46. Epub 2005 Aug 22.

PMID:
16115757
47.

Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells.

Skvortsova I, Popper BA, Skvortsov S, Saurer M, Auer T, Moser R, Kamleitner H, Zwierzina H, Lukas P.

J Radiat Res. 2005 Jun;46(2):241-8.

48.

Different proteome pattern of epidermal growth factor receptor-positive colorectal cancer cell lines that are responsive and nonresponsive to C225 antibody treatment.

Skvortsov S, Sarg B, Loeffler-Ragg J, Skvortsova I, Lindner H, Werner Ott H, Lukas P, Illmensee K, Zwierzina H.

Mol Cancer Ther. 2004 Dec;3(12):1551-8.

49.

Effects of paclitaxel and docetaxel on EGFR-expressing human carcinoma cells under normoxic versus hypoxic conditions in vitro.

Skvortsova I, Skvortsov S, Haidenberger A, Devries A, Nevinny-Stickel M, Saurer M, Lukas P, Seppi T.

J Chemother. 2004 Aug;16(4):372-80.

PMID:
15332713
50.

[Effect of inositol triphosphate receptor blocker heparin on contractions in the Lampetra fluviatilis muscle].

Nasledov GA, Skvortsova IV, Skorobovichuk NF.

Zh Evol Biokhim Fiziol. 2001 Jan-Feb;37(1):74-6. Russian. No abstract available.

PMID:
11424532

Supplemental Content

Loading ...
Support Center